Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
7503
REVBW
Revelation Biosciences, Inc. - Warrant
0.0062 USD0.00%-37.37%-46.09%-52.31%4.22 M USD
7509
SXTPW
60 Degrees Pharmaceuticals, Inc. - Warrant
0.0298 USD0.00%+6.43%-20.74%-70.20%3.88 M USD
7520
CDTTW
CDT Equity Inc. - Warrant
0.0110 USD0.00%-30.38%-17.91%-12.00%1.80 M USD
7525
SLXNW
Silexion Therapeutics Corp - Warrant
0.0250 USD0.00%-16.11%-37.50%-37.50%1.07 M USD

Frequently asked questions about Galecto Inc

What is the Galecto Inc stock price today?

The current price of Galecto Inc (GLTO) is 28.69. Over the past 24 hours, the stock has changed by 0.00%. Follow the GLTO chart for real-time price dynamics.

What is the stock ticker of Galecto Inc?

Galecto Inc trades under the ticker GLTO. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Galecto Inc stock going up?

GLTO has changed by -0.21% over the last week, -6.00% over the last month, and +764.16% over the last year. Review the chart to see whether the current move is part of a broader trend.

How many employees does Galecto Inc have?

As of the latest available data, Galecto Inc has 7 employees. Workforce size can provide additional context about the company's scale and operations.

How can I buy Galecto Inc stock?

You can buy Galecto Inc (GLTO) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Galecto Inc stock?

Investing in Galecto Inc requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the GLTO chart and related analysis on metatrader.com as part of your research.

Galecto Inc

Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark. The company builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. Galecto's lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, in which there is high unmet medical need.

News